Selected Publications:

Ghizzi A., Carlo-Stella C., Bossi M.T., Gorini M. “Overshoot” phenomenon in circulating granulocytic  progenitor cell growth during remission of blast crisis in a case of CML.

Haematologica 67:853-859, 1982


Dezza L., Cazzola M., Bergamaschi G., Burgio V.L., Carlo-Stella C., Fenoglio C., Ghizzi A., Nalli G., Sacchi F., Ascari E. Myelodysplastic syndrome with monosomy 7 in adulthood: a distinct preleukemic disorder.

Haematologica 68:723-735, 1983


Ghizzi A., Carlo-Stella C., Bossi M.T., Gorini M. Spectrum of bone marrow cluster- and colony-forming units in healthy adult subjects.

Haematologica 69:1-9, 1984


Bobbio Pallavicini E., Ghizzi A., Luliri P., Carlo-Stella C., Gorini M. Circulating granulocytic progenitor cell (CFU-GM) cultures in a long surviving case of smouldering leukemia.

Haematologica 69:687-694, 1984


Carlo-Stella C., Ghizzi A., Bonfichi M., Pedrazzoli P., Bobbio Pallavicini E., Gorini M. Cell- and humoral-mediated granulopoietic failure detected by CFU-GM assay in one case of Felty’s syndrome unresponsive to prednisone treatment.

Haematologica 70:296-302, 1985


Ghizzi A., Carlo-Stella C., Pedrazzoli P., Bobbio Pallavicini E., Gorini M., Ascari E. Significance of marrow-blood barrier for CFU-GM in patients with acute nonlymphoid leukemia (AnLL).

Haematologica 70:303-308, 1985


Carlo-Stella C., Ghizzi A., Pedrazzoli P., Gorini M., Ascari E. Clinical relevance of two in vitro tests based on CFU-GM assay in the study of granulopoietic failure.

Haematologica 70:487-494, 1985


Carlo-Stella C., Ganser A., Hoelzer D. Defective “in vitro” growth of the hemopoietic progenitor cells CFU-GEM, BFU-E, CFU-Mk and CFU-GM in the acquired immunodeficiency syndrome (AIDS).

J Clin Invest 80:286-293, 1987


Carlo-Stella C., Cazzola M., Ganser A., Barosi G., Dezza L., Meloni F., Pedrazzoli P., Hoelzer D., Ascari E. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hemopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia.

Blood 70:1014-1019, 1987


Ganser A., Carlo-Stella C., Greher J., Völkers B., Hoelzer D. Effect of recombinant interferons alpha and gamma on human bone marrow derived megakaryocytic progenitor cells.

Blood 70:1173-1179, 1987


Carlo-Stella C., Cazzola M., Ganser A., Meloni F., Pedrazzoli P., Bernasconi P., Invernizzi R., Hoelzer D., Ascari E. Recombinant interferon gamma induces in vitro monocytic differentiation of blast cells from patients with acute non lymphocytic leukemia and myelodysplastic syndromes.

Leukemia 2:55-59, 1988


Carlo-Stella C., Bergamaschi G., Nalli G., Cazzola M. “In vitro” megakaryocytopoiesis in patients with HIV-related thrombocytopenic purpura.

Haematologica 73:25-30, 1988


Dezza L., Cazzola M., Bergamaschi G., Carlo-Stella C., Recalde H. R., Pedrazzoli P. Effects of recombinant human H-subunit and L-subunit ferritins on in vitro growth of human granulocyte-monocyte progenitors.

Br J Haematol 68:367-372, 1988


Giordano M., Ucci G., Riccardi A., Girino M., Danova M., Carlo-Stella C., Pedrazzoli P., Cazzola M. Effect of recombinant gamma interferon on the proliferative activity of cultured leukemic cells.

Haematologica 73:187-189, 1988


Ganser A., Carlo-Stella C., Bartram C.R., Boehm Th., Heil G., Henglein B., Müller H., Raghavachar An., von Briesen H., Griesinger F., Völkers B., Ruebsamen-Waigmann, Helm E.B., Hoelzer D. Establishment of two Epstein-Barr negative Burkitt cell lines from a patient with AIDS and B-cell lymphoma.

Blood 72:1255-1260, 1988


Carlo-Stella C., Cazzola M., Ganser A., Bergamaschi G., Pedrazzoli P., Hoelzer D., Ascari E. Synergistic antiproliferative effect of recombinant interferon gamma with recombinant interferon alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, CFU-GM).

Blood 72:1293-1299, 1988


Dezza L., Cazzola M., Danova M., Carlo-Stella C., Bergamaschi G., Brugnatelli S., Invernizzi R., Mazzini G., Riccardi A., Ascari E. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies.

Leukemia 3:104-107, 1989


Carlo-Stella C., Cazzola M., Bernasconi P., Bergamaschi G., Dezza L., Pedrazzoli P., Rosti V., Tomaselli S. Zappone E. In vitro growth of bone marrow-derived multipotent and lineage-restricted haemopoietic progenitor cells in myelodysplastic syndromes.

Haematologica 74:181-186, 1989


Carlo-Stella C., Cazzola M., Bergamaschi G., Bernasconi P., Dezza L., Invernizzi R., Pedrazzoli P. Growth of human hematopoietic colonies from patients with myelodysplastic syndromes in response to recombinant human granulocyte-macrophage colony-stimulating factor.

Leukemia 3:363-366, 1989


Rosti V., Carlo-Stella C., Pedrazzoli P., Cazzola M. In vitro and in vivo effects of recombinant interferon gamma on the growth of hematopoietic progenitor cells from patients with myelodysplastic syndrome.

Haematologica 74:435-440, 1989


Bergamaschi G., Carlo-Stella C., Cazzola M., De Fazio P., Pedrazzoli P., Peverali F.A., Della Valle G. Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia.

Leukemia 4:426-430, 1990


Carlo-Stella C., Mangoni L., Almici C., Frassoni F., Fiers W., Rizzoli V. Growth of CD34+ acute myeloblastic leukemia colony-forming cells in response to recombinant hematopoietic growth factors.

Leukemia 4:561-566, 1990


Bergamaschi G., Carlo-Stella C., Cattoretti G., Invernizzi R., Maserati E., Nalli G., Pedrazzoli P., Peverali F.A., Della Valle G., Ascari E., Cazzola M. Establishment and characterization of a B-cell line derived from a patient with a myelodysplastic syndrome which expresses myelomonocytic and lymphoid markers.

Br J Haematol 78:167-172, 1991


Almici C., Mangoni L., Carlo-Stella C., Rizzoli V. Human peripheral blood mononuclear cell subfractionation using counterflow centrifugation elutriation.

Haematologica 76:89-93, 1991


Ottmann O.G., Carlo-Stella C., Eder M., Reutzel P., Ströcker S., Hoelzer D., Ganser A. Regulation of early hematopoiesis in serum-deprived cultures of mafosfamide-treated and untreated CD34-enriched bone marrow cells.

Exp Hematol 19:773-778, 1991


Carlo-Stella C., Mangoni L., Piovani G., Almici C., Garau D., Caramatti C., Rizzoli V. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte-macrophage colony-stimulating factor.

Bone Marrow Transplant 8:265-273, 1991


Bergamaschi G., Cazzola M., Rosti V., Carlo-Stella C., Santini V., Ponchio L., Peverali F.A., Della Valle G., Rossi Ferrini P., Ascari E. Tumor necrosis factor alpha modulates the messenger RNA expression of hematopoietic growth factor genes in fresh blast cells from patients with acute myeloblastic leukemia.

Leukemia 5:886-891, 1991


Carlo-Stella C., Mangoni L., Almici C., Garau D., Craviotto L., Piovani G., Caramatti C., Rizzoli V. Differential sensitivity of adherent CFU-Blast, CFU-Mix, BFU-E and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.

Exp Hematol 20:328-333, 1992


Carlo-Stella C., Mangoni L., Almici C., Cottafavi L., Meloni G., Mandelli F., Rizzoli V. Use of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.

Blood 80:2412-2418, 1992


Balduini C.L., Carlo-Stella C., Rosti V., Bertolino G., Noris P., Ascari E. Acquired cyclic thrombocytopenia-thrombocytosis with periodic defect of platelet function.

Br J Haematol, 85:718-722, 1993


Carlo-Stella C., Mangoni L., Piovani G., Garau D., Almici C., Rizzoli V. Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients.

Blood 83:1373-1380, 1994


Carlo-Stella C., Mangoni L., Almici C., Caramatti C., Cottafavi L., Dotti G., Rizzoli V. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.

Bone Marrow Transplant 14:425-432, 1994


Dotti G., Carlo-Stella C., Mangoni L., Cottafavi L., Caramatti C., Almici C., Rizzoli V. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.

Haematologica 80:142-145, 1995


Almici C., Mangoni L., Carlo-Stella C., Garau D., Cottafavi L., Rizzoli V. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.

Bone Marrow Transplant 16:95-101, 1995


Almici C., Carlo-Stella C., Mangoni L., Garau D., Cottafavi L., Ventura A., Armanetti M., Rizzoli V. Density separation of umbilical cord blood and recovery of hemopoietic progenitor cells: implications for cord blood banking.

Stem Cells 13:533-540, 1995


Rizzo M.T., Boswell S.H., Mangoni L., Carlo-Stella C., Rizzoli V. Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-α: evidence for a tyrosine-kinase-dependent process.

Blood 86:2967-2975, 1995


Rosti V., Bergamaschi G., Lucotti C., Danova M., Carlo-Stella C., Locatelli F., Tonon L., Mazzini G., Cazzola M. Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors.

Blood 86:3387-3393, 1995


Bonati A., Albertini R., Garau D., Pinelli S., Lunghi P., Almici C., Carlo-Stella C., Rizzoli V., Dall’Aglio P. BCL2 oncogene protein expression in human hematopoietic precursors during fetal life.

Exp Hematol 24:459-465, 1996


Carlo-Stella C., Regazzi E., Garau D., Mangoni L., Rizzo M.T., Bonati A., Dotti G., Almici C., Rizzoli V. Effect of the protein tyrosine kinase inhibitor genistein  on normal and leukemic hematopoietic progenitor cell growth.

Br J Haematol 93:551-557, 1996


Almici C., Carlo-Stella C., Wagner J.E., Rizzoli V. Density separation and cryopreservation of umbilical cord blood cells: evaluation of recovery in short- and long-term cultures.

Acta Haematol 95:171-175, 1996


Almici C., Carlo-Stella C., Rizzoli V., Wagner J.E. Detection of maternal progenitor cells in human umbilical cord blood by single-colony karyotyping.

Blood 88:1520-1521, 1996 (lettera)


Carlo-Stella C., Dotti G., Mangoni L., Regazzi E., Garau D., Rizzo M.T., Savoldo B., Rizzoli V. Selection of myeloid progenitors lacking BCR-ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.

Blood 88:3091-3100, 1996


Rizzo M.T., Carlo-Stella C. Arachidonic acid mediates interleukin-1 and tumor necrosis fator-α induced activation of the c-jun amino-terminal kinases in stromal cells.

Blood 88:3792-3800, 1996


Cesana C., Carlo-Stella C.,* Mangoni L., Regazzi E., Garau D., Caramatti C., Almici C., Rizzoli V. In vitro growth of mobilized peripheral blood progenitor cells is significantly enhanced by stem cell factor.

Stem Cells 15:207-213, 1997                                   * corresponding author


Almici C., Carlo-Stella C., Wagner J.E., Mangoni L., Garau D., Re A., Giachetti R., Cesana C., Rizzoli V. Clonogenic capacity and ex vivo expansion potential of umbilical cord blood progenitor cells are not impaired by cryopreservation.

Bone Marrow Transplant 19:1079-1084, 1997


Carlo-Stella C., Andrizzi C., Regazzi E., Savoldo B., Garau D., Montefusco E., Vignetti M., Mandelli F., Rizzoli V., Meloni G. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with Hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.

Haematologica 82:291-296, 1997


Carlo-Stella C., Tabilio A., Regazzi E., Garau D., La Tagliata R., Trasarti S., Andrizzi C., Vignetti M., Meloni G. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors.

Bone Marrow Transplant 20:465-471, 1997


Di Ianni M., Casciari C., Ciurnelli R., Fulvi A., Bagnis C., Sadelain M., Lucheroni F., Mannoni P., Carlo-Stella C., Martelli M.F., Tabilio A. Retroviral transfer of herpes simplex virus-thymidine kinase and beta-galactosidase genes into U937 cells with bicistronic vector.

Leuk Res 21:951-959, 1997


Almici C., Carlo-Stella C., Wagner J.E., Mangoni L., Garau D., Rizzoli V. Biologic and phenotypic analysis of early hematopoietic cells in umbilical cord blood.

Leukemia 11:2143-2149, 1997


Cesana  C., Giachetti R., Almici C., Garau D., Mangoni L., Pesci A., Carlo-Stella C.: The parallel between CD45 expression and extra-medullary evolution in aggressive myeloma with high serum lactate dehydrogenase.

Haematologica 83:276-279, 1998


Cesana C., Carlo-Stella C.,* Regazzi E., Garau D., Sammarelli G., Caramatti C., Tabilio A., Mangoni L., Rizzoli V. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.

Bone Marrow Transplant 21:561-568, 1998        * corresponding author


Savoldo B., Sammarelli G., Garau D., Regazzi E., Dotti G., Tabilio A., Rizzoli A., Carlo-Stella C. Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells.

Leukemia 12:434-440, 1998


Cilloni D., Garau D., Regazzi E., Sammarelli G., Savoldo B., Caramatti C., Mangoni L., Rizzoli V., Carlo-Stella C. Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing.

Bone Marrow Transplant 23:497-503, 1999


Siena S., Sammarelli G., Grimoldi M.G., Schiavo R., Nozza A., Roncalli M., Mecucci C., Santoro A., Carlo-Stella C. Novel reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia.

Haematologica 84:369-372, 1999


Carlo-Stella C., Regazzi E., Sammarelli G., Colla S., Garau D., Gazit A., Savoldo B., Cilloni D., Tabilio A., Levitzki A., Rizzoli V. Effects of the tyrosine kinase inhibitor AG957 and an anti-Fas receptor antibody on CD34+ chronic myelogenous leukemia progenitor cells.

Blood 93:3973-3982, 1999


Poli P., Buschini A., Spaggiari P., Rizzoli V., Carlo-Stella C., Rossi C. DNA damage by tobacco smoke and some antiblastic drugs evaluated using the Comet assay.

Toxicol Lett 108:267-276, 1999


Di Nicola M., Milanesi M., Magni M., Bregni M., Carlo-Stella C., Longoni P., Tomanin R., Ravagnani F., Jordan C., Gianni A.M. Recombinant adenoviral vector-lipofectamine complex for gene transduction into human T-lymphocytes.

Hum Gene Therapy 10:1875-1884, 1999


Boiron J.-M., Cahn J.-Y., Meloni G., Carlo-Stella C., Bandini G., Reman O., Milpied N., Apperley J., Reiffers J. Chronic myeloid leukemia in first chronic phase not responding to α-interferon: outcome and prognostic factors after autologous transplantation.

Bone Marrow Transplant 24:259-264, 1999


Lo Coco F., Diverio D., Avvisati G., Petti M.C., Meloni G., Pogliani E.M., Biondi A., Rossi G., Carlo-Stella C., Selleri C., Martino B., Specchia G., Mandelli F. Therapy of molecular relapse in acute promyelocytic leukemia.

Blood 94:2225-2229, 1999


Rizzo M.T., Regazzi E., Yu W., Garau D., Dugan M., Akard L., Boswell H.S., Cooper M., Geary W., Rizzoli V., Carlo-Stella C. Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells.

Cancer Res 59:5047-5053, 1999


Carlo-Stella C., Cesana C., Regazzi E., Falzetti F., Aversa F., Rizzoli V., Martelli M.F., Tabilio A. Peripheral blood progenitor cell mobilization in healthy donors receiving recombinant human granulocyte colony-stimulating factor.

Exp Hematol 28:216-224, 2000


Bonati A., Carlo-Stella C., Lunghi P., Albertini R., Pinelli S., Migliaccio E., Sammarelli G., Savoldo B., Tabilio A., Dall’Aglio P.P., Pelicci P.G. Selective expression and constitutive phosphorylation of Src-homology-2 and collagen-homology domains proteins in the CD34+ fraction of chronic myelogenous leukemias.

Cancer Res 60:728-732, 2000


Fogli M., Carlo-Stella C., Curti A., Ratta M., Tazzari P.L., Regazzi E., Colla S., Santucci A.M., Tura S., Lemoli R. Transforming growth factor-ß3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis.

Exp Hematol, 28:775-783, 2000


Di Ianni M., Di Florio S., Venditti G., Liberatore C., Lucheroni F., Falzetti F., Terenzi A., Carlo-Stella C., Spinozzi F., Mannoni P., Martelli M.F., Tabilio A. T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection.

Cancer Gene Ther, 7:920-926, 2000


Buschini A., Anceschi E., Carlo-Stella C., Regazzi E., Rizzoli V., Poli P., Rossi C. Amifostine (WR-2721) selective protection against Melphalan genotoxicity.

Leukemia 14:1642-1651, 2000


Di Nicola M., Carlo-Stella C., Milanesi M., Magni M., Longoni P., Mortarini R., Anichini A., Tomanin R., Scarpa M., Gianni M.A. Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex.

Br J Haematol 111:344-350, 2000


Cilloni D., Carlo-Stella C.,* Falzetti F., Sammarelli G., Regazzi E., Colla S., Rizzoli V., Aversa F., Martelli M.F., Tabilio A. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell depleted hematopoietic stem cell transplantation.

Blood 96:3637-3643, 2000                                       * corresponding author


Lunghi P., Tabilio A., Pinelli S., Valmadre G., Ridolo E., Albertini R., Carlo-Stella C., Dall’Aglio P.P., Pelicci P.G., Bonati A. Expression and activation of SHC/MAP kinase parthway in primary acute myeloid leukemia blasts.

Haematologica 2:70-80, 2001


Buschini A., Alessandrini C., Martino A., Pasini L., Rizzoli V., Carlo-Stella C., Poli P., Rossi C. Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells.

Biochem Pharmacol 63:967-975, 2002


Di Nicola M., Carlo-Stella C.,* Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli.

Blood 99:3838-3843, 2002                                       * corresponding author


Matteucci P., Magni M., Di Nicola M., Carlo-Stella C., Uberti C., Gianni A.M. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody.

Blood 100:1104-1105, 2002


Carlo-Stella C., Di Nicola M., Magni M., Longoni P., Milanesi M., Stucchi C., Cleris L., Formelli F., Gianni M.A. Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice.

Cancer Res 62:6152-6157, 2002


Magni M., Di Nicola M., Carlo-Stella C., Matteucci P., Lavazza C., Grisanti S., Bifulco C., Pilotti S., Papini D., Rosai J., Gianni A.M. Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor.

Leuk Res 26:1131-1133, 2002


Lunghi P., Tabilio A., Dall’Aglio P.P., Ridolo E., Carlo-Stella C., Pelicci P.G., Bonati A. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts.

Leukemia 17:1783-1793, 2003


Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, Rambaldi A, Cortelazzo S, Patti C, Parvis G, Benedetti F, Capria S, Corradini P, Tarella C, Barbui T. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

Blood 102:749-755, 2003


Di Nicola M, Carlo-Stella C, Anichini A, Mortarini R, Guidetti A, Tragni G, Gallino F, Del Vecchio M, Ravagnani F, Morelli D, Chaplin P, Arndtz N, Sutter G, Drexler I, Parmiani G, Cascinelli N, Gianni AM. Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34+ cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.

Hum Gene Therapy 14:1347–1360, 2003


Di Nicola M, Napoli S, Anichini A, Mortarini R, Romagnoli L, Magni M, Matteucci P, Baldassarri P, Bersani I, Carlo-Stella C, Gianni AM. Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection.

Haematologica 88:1396-404, 2003


Carlo-Stella C., Di Nicola M., Longoni P., Milani R., Milanesi M., Guidetti A., Haanstra K., Jonker M., Cleris L., Magni M., Formelli F., Gianni A.M. Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with Defibrotide and recombinant human granulocyte colony-stimulating factor.

Exp Hematol 32:68-75, 2004


Carlo-Stella C., Di Nicola M., Milani R., Guidetti A., Magni M., Milanesi M., Longoni P., Matteucci P., Formelli F., Ravagnani F., Corradini P., Gianni A.M. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers.

Blood 103:3287-3295, 2004


Khobta A., Carlo-Stella C., Capranico G. Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene.

Cancer Res 64:2656-2662, 2004


Carlo-Stella C., Di Nicola M., Milani R., Longoni P., Milanesi M., Bifulco C., Stucchi C., Guidetti A., Cleris L., Formelli F., Garotta G., Gianni A.M. Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH).

Exp Hematol 32:171-178, 2004


Di Nicola M., Carlo-Stella C., Mortarini R., Baldassari P., Guidetti A., Gallino F., Del Vecchio M., Ravagnani F., Magni M., Chaplin P., Cascinelli N., Parmiani G., Gianni A.M., Anichini A. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.

Clin Cancer Res 10:5381-5390, 2004


Di Nicola M., Carlo-Stella C., Mariotti J., Devizzi L., Massimino M., Cabras A., Magni M., Matteucci P., Guidetti A., Gandola L., Gianni A.M. High response rate and manageable toxicity with an intensive, short-term chemotherapy program for Burkitt’s lymphoma in adults.

Br J Haematol 126:815-820, 2004


Ricca I., Compagno M., Ladetto M., Rocci A., Dell’Aquila M., Omedè P., De Marco F., D’Antico S., Caracciolo D., Ferrero D., Carlo-Stella C., Tarella C. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.

Leukemia 19:644-651, 2005


Dodero A., Carrabba M., Milani R., Rizzo E., Raganato A., Montefusco V., Farina L., Milanesi M., Longoni P., Carlo-Stella C., Corradini P. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.

Exp Hematol 33:920-927, 2005


Anichini A., Mortarini R., Romagnoli L., Baldassari P., Cabras A., Carlo-Stella C., Gianni A.M., Di Nicola M. Skewed T cell differentiation in indolent non-Hodgkin’s lymphoma patients reversed by ex-vivo T cell culture with {gamma}c-cytokines.

Blood 107:602-609, 2006


Carlo-Stella C., Di Nicola M., Turco M.C., Cleris L., Lavazza C., Longoni P., Milanesi M., Magni M., Ammirante M., Leone A., Nagy Z., Gioffrè W.R., Formelli F., Gianni A.M. The anti-HLA-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing NOD/SCID mice.

Cancer Res 66:1799-1808, 2006


Matteucci P., Carlo-Stella C., Di Nicola M., Magni M., Guidetti A., Marchesi M., Gianni A.M. Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside.

Haematologica 91:255-257, 2006


Carlo-Stella C., Guidetti A., Di Nicola M., Longoni P., Cleris L., Lavazza C., Milanesi M., Milani R., Carrabba M., Farina L., Formelli F., Gianni A.M., Corradini P. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.

Exp Hematol 34:721-727, 2006


Carlo-Stella C., Lavazza C., Di Nicola M., Cleris L., Longoni P., Milanesi M., Magni M., Morelli D., Gloghini A., Carbone A., Gianni A.M. Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (mTRAIL).

Hum Gene Therapy 17:1225-1240, 2006


Carlo-Stella C., Di Nicola M., Longoni P., Cleris L., Lavazza C., Milani R., Milanesi M., Magni M., Pace V., Colotta F., Avanzini M.A., Formelli F., Gianni A.M. Placental growth factor-1 potentiates hematopoietic progenitor cell mobilization induced by granulocyte colony-stimulating factor in mice and nonhuman primates.

Stem Cells 25:252-261, 2007


Rossi E., Picozzi P., Bodega B., Lavazza C., Carlo-Stella C., Marozzi A., Ginelli E.  Forced expression of RDH10 gene retards growth of HepG2 cells.

Cancer Biol Ther 6:238-244, 2007


Rocci A., Ricca I., Dellacasa C., Longoni P., Compagno M., Francese R., Lobetti Bodoni C., Manzini P., Caracciolo D., Boccadoro M., Ferrero D., Ladetto M., Carlo-Stella C., Tarella C. Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir.

Exp Hematol 35:673-681, 2007


Carlo-Stella C., Guidetti A., Di Nicola M., Lavazza C., Cleris L., Sia D., Longoni P., Milanesi M., Magni M., Nagy Z., Corradini P., Carbone A., Formelli F., Gianni A.M. Interferon γ enhances the anti-myeloma activity of the fully human anti-HLA-DR monoclonal antibody 1D09C3.

Cancer Res 67:3269-3275, 2007


Lavazza C., Carlo-Stella C.,* Di Nicola M., Longoni P., Milanesi M., Magni M., Gianni A.M. Highly efficient gene transfer into mobilized CD34+ hematopoietic cells using serotype-5 adenoviral vectors and BoosterExpress™ Reagent.

Exp Hematol 35:888-897, 2007                              * corresponding author


Zappasodi R., Di Nicola M., Carlo-Stella C., Mortarini R., Molla A., Vegetti C., Albani S., Anichini A., Gianni A.M. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.

Haematologica 93:1523-1534, 2008


Devizzi L., Guidetti A., Tarella C., Magni M., Matteucci P., Seregni E., Chiesa C., Bombardieri E., Di Nicola M., Carlo-Stella C., Gianni A.M. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

J Clin Oncol 26:5175-5182, 2008


Di Nicola M., Zappasodi R., Carlo-Stella C., Mortarini R., Pupa S.M., Magni M., Devizzi L., Matteucci P., Baldassari P., Ravagnani F., Cabras A., Anichini A., Gianni A.M. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.

Blood 113:18-27, 2009


Magni M., Di Nicola M., Carlo-Stella C., Matteucci P., Devizzi L., Tarella C., Benedetti F., Martelli M., Patti C., Parvis G., Rambaldi A., Barbui T., Gianni A.M. High-dose sequential chemotherapy and in vivo Rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen.

Bone Marrow Transplant 43:509-511, 2009


Dodero A., Carniti C., Raganato A., Vendramin A., Farina L., Spina F., Carlo-Stella  C., Di Terlizzi S., Milanesi M., Longoni P., Gandola L., Lombardo C., Corradini P. Haploidentical stem cell transplantation following a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: post-transplant CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.

Blood 113:4771-4779, 2009


Chiesa C., Botta F., Coliva A., Maccauro M., Devizzi L., Guidetti A., Carlo-Stella C., Seregni E., Gianni A.M., Bombardieri E. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®).

Eur J Nucl Med Mol Imaging 36:1745-57, 2009


Righi M., Giacomini A., Lavazza C., Sia D., Carlo-Stella C., Gianni A.M. A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.

Lab Invest 89:1063-70, 2009


De Filippi P., Zecca M., Lisini D., Rosti V., Cagioni C., Carlo-Stella C., Radi O., Veggiotti P., Mastronuzzi A., Acquaviva A., D’Ambrosio A., Locatelli F., Danesino C. Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia.

Br J Haematol 147:706–9, 2009


Ruella M., Rocci A., Ricca I., Carniti C., Bodoni C.L., Ladetto M., Caracciolo D., Boccadoro M., Carlo-Stella C., Corradini P., Tarella C. Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status.

Bone Marrow Transplant 45: 505-12, 2010


Magni M., Di Nicola M., Carlo-Stella C., Devizzi L., Guidetti A., Matteucci P., Gianni A.M. Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up.

Bone Marrow Transplant 45:1119-1120, 2010


Magni M., Di Nicola M., Testi A., Cabras A., Devizzi L., Guidetti A., Matteucci P., Viviani S., Bonfante V., Carniti C., Ricca I., Carbone A., Carlo-Stella C., Gianni A.M. Radioimmunotherapy and secondary leukemia: A case report.

Leuk Res 34:e1-4, 2010


Lavazza C., Carlo-Stella C.,* Giacomini A., Cleris L., Righi M., Sia D., Di Nicola M., Magni M., Longoni P., Milanesi M., Francolini M., Gloghini A., Carbone A., Formelli F., Gianni A.M. Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) target both tumor cells and tumor vasculature.

Blood 115: 2231-40, 2010                                        * corresponding author


Viviani S., Di Nicola M., Bonfante V., Di Stasi A., Carlo-Stella C., Matteucci P., Magni M., Devizzi L., Valagussa P., Gianni A.M. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.

Leuk Lymphoma 51:1251-9, 2010


Zappasodi R., Pupa S.M., Ghedini G.C., Bongarzone I., Magni M., Cabras A.D., Colombo M.P., Carlo-Stella C., Gianni A.M., Di Nicola M. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.

Cancer Res, 70:9062-72, 2010


Servida F., Lecis D., Scavullo C., Drago C., Seneci P., Carlo-Stella C., Manzoni L., Polli E., Lambertenghi Deliliers G., Delia D., Onida F. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.

Invest New Drugs 29:1264-75, 2011


Guidetti A., Carlo-Stella C.,* Ruella M., Miceli R., Devizzi L., Locatelli S.L., Giacomini A., Testi A., Buttiglieri S., Risso A., Mariani L., Di Nicola M., Passera R., Tarella C., Gianni A.M. Myeloablative doses of Yttrium-90-Ibritumomab Tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.

Cancer 117:5074-5084, 2011                          * corresponding author


Zappasodi R, Bongarzone I, Ghedini GC, Castagnoli L, Cabras AD, Messina A, Tortoreto M, Tripodo C, Magni M, Carlo-Stella C, Gianni AM, Pupa SM, Di Nicola M. Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.

Blood 118:4421-4430, 2011


Tassi E., Zanon M., Vegetti C., Molla A., Bersani I., Perotti V., Pennati M., Zaffaroni N., Milella M., Ferrone S., Carlo-Stella C., Gianni A.M., Mortarini R., Anichini A. Role of apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways.

Clin Cancer Res 18:3316-3327, 2012


Guidetti A., Carlo-Stella C.,* Locatelli S.L., Malorni W., Pierdominici M., Barbati C., Mortarini R., Devizzi L., Matteucci P., Marchianò A., Lanocita R., Farina L., Dodero A., Tarella C., Di Nicola M., Corradini P., Anichini A., Gianni A.M. Phase II study of sorafenib in patients with relapsed or refractory lymphoma.

Br J Haematol 158:108-119, 2012                         * corresponding author


De Filippi P, Zecca M, Novara F, Lisini D, Maserati E, Pasquali F, Rosti V, Carlo-Stella C, Zavras N, Cagioni C, Zuffardi O, Pagliara D, Danesino C, Locatelli F. The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.

Pediatr Blood Cancer 59:580-582, 2012


Lobetti-Bodoni C., Ferrero D., Genuardi E., Passera R., Bernocco E., Sia D., Grignani G., Crisà E., Monitillo L., Rocci A., Drandi D., Giai V., Zanni M., Boi M., Isaia G., Barbero D., Lunghi M., Abruzzese E., Radaelli F., Pini M., Pregno P., Carlo-Stella C., Gaidano G., Boccadoro M., Ladetto M. Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment.

Mech Ageing Dev 133:479-488, 2012


Magni M., Di Nicola M., Carlo-Stella C., Matteucci P., Devizzi L., Guidetti A., Ravagnani F., Gianni A.M. Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma.

Am J Blood Res 2:105-112, 2012


Locatelli S.L., Giacomini A., Guidetti A., Clezris L., Mortarini R., Anichini A., Gianni A.M., Carlo-Stella C. Perifosine and Sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin Lymphoma cell line xenografts.

Leukemia 27: 1677-87, 2013


Righi M., Giacomini A., Cleris L., Carlo-Stella C. 3D quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies.

PLoS One 8:e59691, 2013


Giacomini A., Righi M., Cleris L., Locatelli S.L., Mitola S., Daidone M.G., Gianni A.M., Carlo-Stella C. Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells.

Angiogenesis 16:707-22, 2013


Carlo-Stella C., Locatelli S.L., Giacomini A., Cleris L., Saba E., Righi M., Guidetti A., Gianni A.M. Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.

PLoS One 8:e61603, 2013


Farina L., Spina F., Guidetti A., Longoni P., Ravagnani F., Dodero A., Montefusco V., Carlo-Stella C., Corradini P.: Peripheral blood CD34+ cell monitoring after cyclophosphamide and granuclocyte colony-stimulating factor: an algorithm for the pre-emptive use of Plerixafor.

Leuk Lymphoma 55:331-336, 2014


Devizzi L., Guidetti A., Seregni E., Passera R., Maccauro M., Magni M., Testi A., Di Nicola M., Tarella C., Matteucci P., Viviani S., Ruella M, Carlo-Stella C., Chiesa C., Cox M.C., Bombardieri E., Gianni A.M. Long-term results of autologous hematopoietic stem-cell transplantation after high-dose 90Y-Ibritumomab Tiuxetan for patients with poor-risk non-Hodgkin’s lymphoma not eligible for high-dose BEAM.

J Clin Oncol 31:2974-2976, 2013


Marconi M., Ascione B., Ciarlo L., Vona R., Garofalo T., Sorice M., Gianni A.M., Locatelli S.L., Carlo-Stella C., Malorni W., Matarrese P. Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B cell hematologic malignancies.

Cell Death and Disease 4:e863, 2013


Farina L., Guidetti A., Spina F., Roncari L., Longoni P., Ravagnani F., Carlo-Stella C., Corradini P.: Plerixafor ‘on demand’: results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy + granulocyte-colony-stimulating factor.

Bone Marrow Transplant 49:453-455, 2014


Necchi A., Miceli R., Pedrazzoli P., Giannatempo P., Secondino S., Di Nicola M., Farè E., Raggi D., Magni M., Matteucci P., Longoni P., Milanesi M., Ravagnani F., Arienti F., Nicolai N., Salvioni R., Carlo-Stella C.,* Gianni A.M. Predictors of CD34+ cell mobilization and collection in adult males with germ cell tumors: implications for the salvage treatment strategy.

Clin Genitourin Cancer 12:196-202.e1, 2014    *corresponding author


Magni M., Di Nicola M., Patti C., Scimè R., Mulè A., Rambaldi A., Intermesoli T., Viero P., Tarella C., Gueli A., Bergui L., Trentin L., Barzan A., Benedetti F., Ambrosetti A., Di Raimondo F., Chiarenza A., Parvis G., Billio A., Attolico I., Olivieri A., Montanari M., Carlo-Stella C., Matteucci P., Devizzi L., Guidetti A., Viviani S., Valagussa P., Gianni A.M.: Results of a randomised trial comparing high-dose chemotherapy plus auto-SCT and R-FC in CLL at diagnosis.

Bone Marrow Transpl 49:485-491, 2014


Castagna L., Crocchiolo R., Furst S., Bramanti S., El Cheik J.,  Sarina B., Granata A., Mauro E., Faucher C., Mohty B., Harbi S., Chabannon C., Carlo-Stella C., Santoro A., Blaise D. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantion cyclophosphamide.*

Biol Blood Marrow Transplant 20:724-729, 2014                * Editorial


Locatelli S.L., Cleris L., Stirparo G., Tartari S., Saba E., Pierdominici M., Malorni W., Carbone A., Anichini A., Carlo-Stella C. BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.

Leukemia 28:1861-1871, 2014


Anastasia A., Carlo-Stella C.,* Corradini P., Salvi F., Rusconi C., Pulsoni A., Hohaus S., Pregno P., Viviani S., Brusamolino E., Luminari S., Giordano L., Santoro A.: Bendamustine for Hodgkin Lymphoma Who Had Failed Autologous or Autologous and Allogeneic Stem Cell Transplantation: A Retrospective Study of the Fondazione Italiana Linfomi (FIL).

Br J Haematol 166:140-142, 2014            * corresponding author


Colasanti T., Vomero M., Alessandri C., Barbati C., Maselli A., Camperio C., Conti F., Tinari A., Carlo-Stella C., Tuosto L., Benincasa D., Valesini G., Malorni W., Pierdominici M., Ortona E. Role of α-synuclein in autophagy modulation of primary human T lymphocytes.

Cell Death Dis 5:e1265, 2014


Guidetti A.,* Carlo-Stella C.,* Locatelli S.L., Malorni W., Mortarini R., Viviani S., Russo D., Marchianò A., Sorasio R., Dodero A., Farina L., Giordano L., Di Nicola M., Anichini A., Corradini P., Gianni A.M.: Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases.

Clin Cancer Res 20:5641-5651, 2014                 * Equal contribution


Grazia G., Vegetti C., Benigni F., Penna I., Perotti V., Tassi E., Bersani I., Canevari S., Carlo-Stella C., Gianni A.M., Mortarini R., Anichini A.: Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.

Cell Death Dis 5:e1434, 2014


Castagna L., Bramanti S., Furst S., Giordano L., Crocchiolo R., Sarina B., Mauro E., Morabito L., Bouabdallah R., Coso D., Balzarotti M., Broussais F., El Cheick J., Carlo-Stella C., Brusamolino E., Blaise D., Santoro A.: Nonmyeloablative conditioning, unmanipulated haploidentical stem cell  transplantation and post-infusion cyclophosphamide for advanced lymphomas.

Bone Marrow Transplant 49:1475-1480, 2014


Pennati M., Sbarra S., De Cesare M., Lopergolo A., Locatelli S.L., Campi E., Daidone M.G., Carlo-Stella C., Gianni A.M., Zaffaroni N.: YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 up-regulation.

Int J Cancer 136:299-309, 2015


Necchi A., Mariani L., Di Nicola M., Lo Vullo S., Nicolai N., Giannatempo P., Raggi D., Farè E., Magni M., Piva L., Matteucci P., Catanzaro M., Biasoni D., Torelli T., Stagni S., Bengala C., Barone C., Schiavetto I., Siena S., Carlo-Stella C., Pizzocaro G., Salvioni R., Gianni A.M.: High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment for patients with poor prognosis germ cell tumors: mature results of a randomized phase II Italian study.

Ann Oncol 26:167-172, 2015


Roberto A., Castagna L., Gandolfi S., Zanon V., Bramanti S., Sarina B., Crocchiolo R., Todisco E., Carlo-Stella C., Tentorio P., Timofeeva I., Santoro A., Della Bella S., Roederer M., Mavilio D., Lugli E.: B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY.

Bone Marrow Transplant 50:317-319, 2015


Reichel J., Chadburn A., Rubinstein PG., Giulino-Roth L., Tam W., Liu Y., Gaiolla R., Eng K., Brody J., Inghirami G., Carlo-Stella C., Santoro A., Rahal D., Totonchy J., Elemento O., Cesarman E., Roshal M.: Flow-sorting and exome sequencing reveals the oncogenome of primary Hodgkin and Reed-Sternberg cells.

Blood 125:1061-1072, 2015


Castagna L., Crocchiolo R., Giordano L., Bramanti S., Carlo-Stella C., Sarina B., Chiti A., Mauro E., Gandolfi S., Todisco E., Balzarotti E., Anastasia A., Magagnoli M., Brusamolino E., Santoro A.: High dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.

Bone Marrow Transplant 50:499-504, 2015


Crocchiolo R., Bramanti S., Vai A., Sarina B., Mineri R., Casari E., Tordato F., Mauro E., Timofeeva I., Lugli E., Mavilio D., Carlo-Stella C., Santoro A., Castagna L.: Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.

Transpl Infect Dis 17:242-249, 2015


Carlo-Stella C., Ricci F., Dalto S., Mazza R., Malagola M., Patriarca F., Viviani S., Russo D., Giordano L., Castagna L., Corradini P., Santoro A.: Brentuximab Vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a Named Patient Programme at four Italian centers.

Oncologist 20:323-328, 2015


Roberto A., Castagna L., Zanon V., Bramanti S., Crocchiolo R., McLaren J.E., Gandolfi S., Tentorio P., Sarina B., Timofeeva I., Santoro A., Carlo-Stella C., Bruno B., Carniti C., Corradini P., Gostick E., Ladell K., Price D.A., Roederer M., Mavilio D., Lugli E.: Role of naïve-derived T memory stem cells in T cell reconstitution following allogeneic transplantation.

Blood 125:2855-2864, 2015


Crocchiolo R., Castagna L., Garciaz S., Fürst S., Cheikh J.E., Sarina B., Bramanti S., Granata A., Vai A., Harbi S., Morabito L., Mohty B., Giordano L., Devillier R., Coso D., Balzarotti M., Chabannon C., Carlo-Stella C., Santoro A., Bouabdallah R., Blaise D.: Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients.

Haematologica 100:e423-7, 2015


Devillier R., Bramanti S., Fürst S., Sarina B., El-Cheikh J., Crocchiolo R., Granata A., Chabannon C., Morabito L., Harbi S., Faucher C., Santoro A., Weiller P.J., Vey N., Carlo-Stella C., Castagna L., Blaise D.: T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic. syndromes.

Bone Marrow Transplant 51:194-8, 2016


Castagna L., Bramanti S., Furst S., Giordano L., Sarina B., Crocchiolo R., El-Cheikh J., Granata A., Morabito L., Mauro E., Faucher C., Mohty B., Harbi S., Devillier R., Chabannon C., Carlo-Stella C., Santoro A., Blaise D.: Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.

Bone Marrow Transplant 51:462-5, 2016


Bramanti S., Nocco A., Mauro E., Milone G., Morabito L., Sarina B., Crocchiolo R., Timofeeva I., Capizzuto R., Carlo-Stella C., Santoro A., Castagna L.: Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation.

Transfusion 56:1096-1100, 2016


Crocchiolo R., Castagna L., Furst S., Devillier R., Sarina B., Bramanti S., El-Cheikh J., Granata A., Harbi S., Morabito L., Faucher C., Rimondo A., Girardi D., Mohty B., Calmels B., Carlo-Stella C., Chabannon C., Bouabdallah R., Santoro A., Vey N., Weiller P.J., Blaise D.: The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.

Bone Marrow Transplant 51:1134-6, 2016


Santoro A., Mazza R., Pulsoni A., Re A., Bonfichi M., Zilioli V.R., Salvi F., Merli F., Anastasia A., Luminari S., Annechini G., Gotti M., Peli A., Liberati A.M., Di Renzo N., Castagna L., Giordano L., Carlo-Stella C.: Bendamustine in combination with Gemcitabine and Vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study.

J Clin Oncol 34:3293-9, 2016


Locatelli S.L., Careddu G., Inghirami G., Castagna L., Sportelli P., Santoro S., Carlo-Stella C.: The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.

Leukemia 30:2402-2405, 2016


Castagna L., Sarina B., Crocchiolo R., Bramanti S., Furst S., Devillier R., Coso D., Bouabdallah R., Mokart D., Morabito L., Harbi S., Giordano L., Rimondo A., Weiller P.J., Carlo-Stella C., Santoro A., Chabannon C., Blaise D.: Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.

Bone Marrow Transplant 51:1644-1646, 2016


Locatelli S.L., Careddu G., Stirparo G.G., Castagna L., Santoro A., Carlo-Stella C.: Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.

Sci Rep 6:35745, 2016


Merryman R.W., Kim H.T., Zinzani P.L., Carlo-Stella C., Ansell S.M., Perales M.A., Avigdor A., Halwani A.S., Houot R., Marchand T., Dhedin N., Lescaut W., Thiebaut-Bertrand A., François S., Stamatoullas-Bastard A., Rohrlich P-S, Labussière Wallet H., Castagna L., Santoro A., Bachanova V., Bresler S.C., Srivastava A., Kim H., Pesek E., Chammas M., Reynolds C., Ho V.T., Antin J.H., Ritz J., Soiffer R.J., Armand P.: Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after PD-1 Blockade in Relapsed/Refractory Lymphoma.

Blood 129:1380-1388, 2017


Castagna L., Bramanti S., Devillier R., Sarina B., Crocchiolo R., Furst S., Cheikh J.E., Granata A., Faucher C., Harbi S., Morabito L., Mariotti J., Puvinathan S., Weiller P.J., Chabannon C., Mokart D., Carlo-Stella C., Bouabdallah R., Santoro A., Blaise D.: Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.

Bone Marrow Transplant 52:683-688, 2017


Pierdominici M., Maselli A., Locatelli S.L., Ciarlo L., Careddu G., Patrizio M., Ascione B., Tinari A., Carlo- Stella C., Malorni W., Matarrese P., Ortona E.: Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy.

Oncotarget 8:8522-8535, 2017


Broccoli A., Pellegrini C., Di Rocco A., Puccini B., Patti C., Gini G., Mannina D., Tani M., Rusconi C., Romano A., Vanazzi A., Botto B., Carlo-Stella C., Hohaus S., Musto P., Mazza P., Molica S., Corradini P., Fama A., Gaudio F., Merli M., Gravetti A., Gritti G., Arcari A., Tosi P., Liberati A.M., Pinto A., Pavone V., Gherlinzoni F., Naso V., Volpetti S., Trentin L., Goldaniga M.C., Bonfichi M., De Renzo A., Schiavotto C., Spina M., Storti S., Carella A.M., Stefoni V., Argnani L., Zinzani P.L.: Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma.

Haematologica 102:1931-1935, 2017


Sara Trabanelli S., Chevalier M., Martinez Usatorre A., Gomez-Cadena A., Salomé B., Lecciso M., Salvestrini V., Verdeil G., Racle J., Papayannidis C., Morita H., Pizzitola I., Grandclement C., Bohner P., Bruni E., Girotra M., Pallavi R., Falvo P., Leibundgut E., Baerlocher G., Carlo-Stella C., Taurino D., Santoro A., Spinelli O., Rambaldi A., Giarin E., Basso G., Tresoldi C., Ciceri F., Gfeller D., Akdis C., Mazzarella L., Minucci S., Pelicci P.G., Marcenaro E., McKenzie A., Vanhecke D., Coukos G., Mavilio D., Curti A., Derre L., Jandus C.: Tumor-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.

Nature Communications 8:593, 2017


Mariotti J., Devillier R., Bramanti S., Sarina B., Furst S., Granata A., Faucher C., Harbi S., Morabito L., Chabannon C., Carlo-Stella C., Bouabdallah R., Santoro A.,Blaise D., Castagna L.: T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-identical related donors.

Biol Blood Marrow Transplant 24:627-632, 2018


Mariotti J., Bramanti S., Devillier R., Furst S., El Cheikh J., Sarina B., Granata A., Faucher C., Harbi S., Morabito L., Weiller P.J., Chabannon C., Mokart J., Mineri R., Carlo-Stella C., Santoro A., Blaise D., Castagna L.: Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma.

Bone Marrow Transplant 53:366-370, 2018


Spina V., Bruscaggin A., Cuccaro A., Martini M., Di Trani M., Forestieri G., Manzoni M., Condoluci A., Arribas A., Terzi-Di-Bergamo L., Locatelli S.L., Cupelli E., Ceriani L., Moccia A.A., Stathis A., Nassi L., Deambrogi C., Diop F., Guidetti F., Cocomazzi A., Annunziata S., Rufini V., Giordano A., Neri A., Boldorini R., Gerber B., Bertoni F., Ghielmini M., Stüssi G., Santoro A., Cavalli F., Zucca E., Larocca L.M., Gaidano G., Hohaus S., Carlo-Stella C., Rossi D: Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma.

Blood 131:2413-2415, 2018


Carbone A., Gloghini A., Carlo-Stella C.: Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?

Blood 132:17-22, 2018


Mineri R, Mariotti J, Sarina B, Morabito L, Crocchiolo R, Bramanti S, Sarno T, Tordato F, Carlo-Stella C, Santoro A, Castagna L.: Genomic integration of HHV-6 mimicking viral reactivation after autologous stem cell transplantation.

Mediterr J Hematol Infect Dis 10:e2018013, 2018


Sarina B, Mariotti J, Bramanti S, Morabito L, Crocchiolo R, Rimondo A, Tordato F, Pocaterra D, Casari E, De Philippis C, Carlo-Stella C, Santoro A, Castagna L.:  A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.

Transpl Infect Dis 20:e12906, 2018


Righi M, Locatelli SL, Carlo-Stella C, Presta M, Giacomini A.: Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors.

Sci Rep 8:17520, 2018


Locatelli SL, Careddu G, Serio S, Consonni FM, Maeda A, Viswanadha S, Vakkalanka S, Castagna L, Santoro A, Allavena P, Sica A, Carlo-Stella C.: Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530.

Clin Cancer Res 25:1098-1112, 2019


Mariotti J, De Philippis C, Bramanti S, Sarina B, Tordato F, Pocaterra D, Casari E, Carlo-Stella C, Santoro A, Castagna L.: Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide.

Eur J Haematol 102:357-367, 2019


Mariotti J, Granata A, Bramanti S, Devillier R, Furst S, Sarina B, Harbi S, Legrand F, Faucher C, Weiller PJ, Chabannon C, Carlo-Stella C, Santoro A, Blaise  D, Castagna L.: The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete  haploidentical stem cell transplant with post-transplant cyclophosphamide.

Bone Marrow Transplant 2019, doi: 10.1038/s41409-019-0453-0


Crisafulli L, Muggeo S, Uva P, Wang Y, Iwasaki M, Locatelli S, Anselmo A, Colombo FS, Carlo-Stella C, Cleary ML, Villa A, Gentner B, Ficara F.: MicroRNA-127-3p controls murine hematopoietic stem cell maintenance by limiting differentiation.

Haematologica 2019, doi:10.3324/haematol.2018.198499.


Pouillon L, Danese S, Hart A, Fiorino G, Argollo M, Selmi C, Carlo-Stella C, Loeuille D, Costanzo A, Lopez A, Vegni E, Radice S, Gilardi D, Socha M, Fazio M, Gonzalez-Lorenzo M, Bonovas S, Magro F, Peyrin-Biroulet L.: Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.

Aliment Pharmacol Ther 49:1181-1187, 2019







Carlo-Stella C., Cazzola M. Interferons as biologic modulators of hematopoietic cell proliferation and differentiation.

Haematologica 73:225-237, 1988


Rizzoli V., Mangoni L., Carlo-Stella C. Autologous bone marrow transplantation in acute myelogenous leukemia.

Leukemia 6:1101-1106, 1992


Almici C., Carlo-Stella C., Donnenberg A.D., Rizzoli V. Counterflow centrifugal elutriation: present and future.

Bone Marrow Transplant 12:105-108, 1993


Carlo-Stella C. Biological aspects and clinical applications of long-term bone marrow culture: a meeting report.

Haematologica 78:236-238, 1993


Carlo-Stella C., Rizzoli V. Stem cells and stem cell factor(s).

Haematologica 80:1-4, 1995


Rizzoli V., Carlo-Stella C. Stem cell purging: an intriguing dilemma.

Exp Hematol 23:296-302, 1995


Almici C., Carlo-Stella C., Wagner J.E., Rizzoli V. Umbilical cord blood as a source of transplantable hemopoietic stem cells: from research to clinic.

Haematologica 80:473-479, 1995


Carlo-Stella C., Cazzola M., De Fabritiis P., De Vincentiis A., Gianni A.M., Lanza F., Lauria F., Lemoli R.M., Tarella C., Zanon P., Tura S. CD34-positive cells: biology and clinical relevance.

Haematologica 80:367-387, 1995


Carlo-Stella C., Tabilio A. Stem cells and stem cell transplantation.

Haematologica 81:573-587, 1996


Rizzoli V., Carlo-Stella C. Stem cell manipulation: why and how performing peripheral blood progenitor cell purging.

Crit Rev Oncol-Hematol 26:101-115, 1997


Aglietta M., Bertolini F., Carlo-Stella C., De Vincentiis A., Lanata L., Lemoli R.M., Olivieri A., Siena S., Zanon P., Tura S. Ex vivo expansion of hematopoietic cells and their clinical use.

Haematologica 83:824-848, 1998


Bordignon C., Carlo-Stella C., Colombo M.P., De Vincentiis A., Lanata L., Lemoli R.M., Locatelli F., Olivieri A., Rondelli D., Zanon P., Tura S. Cell therapy: achievements and perspectives.

Haematologica 84:1110-1149, 1999


Siena S., Schiavo R., Pedrazzoli P., Carlo-Stella C. Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy.

J Clin Oncol 18:1360-1377, 2000


Ruffini P.A., Di Nicola M., Carlo-Stella C., Siena S., Gianni A.M. Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin’s lymphoma.

Curr Gene Ther 5:511-521, 2005


Carlo-Stella C., Lavazza C., Locatelli A., Viganò L., Gianni A.M., Gianni L. Targeting TRAIL Agonistic Receptors for Cancer Therapy.

Clin Cancer Res 13:2313-2317, 2007


Pierdominici M., Barbati C., Vomero M., Locatelli S.L., Carlo-Stella C., Ortona E., Malorni W. Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders.

Faseb J 28:524-535, 2014


Castagna L., Carlo-Stella C., Mazza R., Santoro A.: Current Role of Autologous and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma

Mediterr J Hematol Infect Dis 7:e2015015, 2015


Carbone A., Gloghini A., Castagna L., Santoro A., Carlo-Stella C.: Primary refractory and early-relapsed Hodgkin’s lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.

J Pathol 237:4-13, 2015


Carlo-Stella C., Santoro A.: Microenvironment-related biomarkers and novel targets in classical Hodgkin’s lymphoma.

Biomark Med 9:807-17, 2015






Mangoni L., Carlo-Stella C., Rizzoli V. Marrow purging with mafosfamide at individual adjusted dose.

In Bone Marrow and Stem Cell Processing: A Manual of Current Techniques, (Areman E., Deeg H.J., Sacher R.A., eds.), pp. 244-249. F. A. Davis Company, 1992


Carlo-Stella C., Mangoni L., Rizzoli V. Trapianto di midollo osseo: metodiche di preparazione e manipolazione cellulare.

In Trattato Italiano di Medicina di Laboratorio: Immunologia Clinica, vol IV, (Dammacco F., ed.), pp. 679-688. Piccin Editore, Padova, 1994


Carlo-Stella C. Le tecniche di selezione delle cellule CD34+.

In Progenitori Emopoietici Circolanti: Aspetti Biologici ed Applicazioni in Oncologia, (Danova M., Brando B., Carlo-Stella C., Riccardi A., eds), pp. 39-45. Collana I Manuali (Serie M.D.) dell’Accademia Nazionale di Medicina, Forum Service Editore, 1996


Carlo-Stella C. Tecniche di coltura dei progenitori emopoietici.

In Progenitori Emopoietici Circolanti: Aspetti Biologici ed Applicazioni in Oncologia, (Danova M., Brando B., Carlo-Stella C., Riccardi A., eds), pp. 63-89. Collana I Manuali (Serie M.D.) dell’Accademia Nazionale di Medicina, Forum Service Editore, 1996


Carlo-Stella C., Savoldo B., Sammarelli G., Regazzi E., Garau D., Rizzoli V. Ruolo terapeutico degli inibitori delle tirosino chinasi.

In Terapie Cellulari e Farmacologiche in Onco-Ematologia, (Barbui T, Bonadonna G., Robustelli della Cuna G., eds), pp. 13-24. Edimes, Pavia, 1998


Carlo-Stella C. Organizzazione del sistema ematopoietico e metodi di quantificazione.

In Manuale di Terapie Cellulare, (Bonadonna G., Martelli M.F., Robustelli della Cuna G., eds), pp. 11-24. Edimes, Pavia, 1999


Carlo-Stella C. Purging delle cellule neoplastiche.

In Manuale di Terapie Cellulare, (Bonadonna G., Martelli M.F., Robustelli della Cuna G., eds), pp. 121-131. Edimes, Pavia, 1999


Rizzoli V., Carlo-Stella C., Lanza F. Trapianto di cellule staminali emopoietiche.

In Malattie del Sangue e degli Organi Emopoietici, 3/ed, (Castoldi G., Liso V., eds), pp. 617-636. MacGraw-Hill, Milano, 2001


Rizzoli V., Carlo-Stella C., Lanza F. Trapianto di cellule staminali emopoietiche.

In Malattie del Sangue e degli Organi Emopoietici, 4/ed, (Castoldi G., Liso V., eds), pp. 619-638. MacGraw-Hill, Milano, 2004


Frassoni F., Carlo-Stella C. La sfida estrema: la plasticità delle cellule staminali.

In Le Risorse Cellulari della Vita, (Burgio R.G., Locatelli F., eds), pp. 131-143. UTET, Torino, 2005


Carlo-Stella C., Frassoni F. Trapianto di cellule staminali mesenchimali: razionale e prospettive.

In Le Risorse Cellulari della Vita, (Burgio R.G., Locatelli F., eds), pp. 185-191. UTET, Torino, 2005


Carlo-Stella C. Cellule staminali emopoietiche.

In Sangue Cordonale, (Bosi A., ed), pp. 67-78. SEE, Firenze, 2007


Carlo-Stella C. Fattori di crescita emopoietici in oncologia.

In Medicina Oncologica, VIII Edizione, (Bonadonna G., Robustelli della Cuna G., Valagussa P., eds), pp. 736-749. Elsevier Masson, Milano, 2007


Carlo-Stella C., Lavazza C., Carbone A., Gianni A.M. Antitumor activity of adenovirally transduced CD34+ cells expressing membrane-bound TRAIL.

In Progress in Gene Therapy – Autologous and Cancer Stem Cell Gene Therapy, Vol. 3, (Bertolotti R., Ozawa K., eds), pp. 373-392. World Scientific Publishing Ltd., London, 2007


Carlo-Stella C., Lavazza C., Carbone A., Gianni A.M. Anticancer cell therapy with TRAIL-armed CD34+ progenitor cells.

In Targeted therapies in cancer : mith or reality?, (Colotta F., Mantovani A., eds.) pp. 100-111. Springer, New York, 2008


Carlo-Stella C., Giacomini A., Locatelli S.L., Lavazza C., Gianni A.M. Targeting TRAIL receptors with genetically-engineered CD34+ hematopoietic stem cells.

In Non-Viral Gene Therap, (Yuan X., ed), pp. 661-678. InTech, Rijeka, 2011


Guidetti A., Giacomini A., Locatelli S.L., Carlo-Stella C. Monoclonal antibodies for targeted treatment of lymphoproliferative neoplasias.

In ESMO Handbook of Clinical Pharmacology of Anti-Cancer Agents, (Sessa C., Gianni L., Garassino M., van Halteren H., eds.), pp. 181-192. ESMO Press, 2012


Carbone A., Tripodo C., Carlo-Stella C., Santoro A., Gloghini A.: The role of inflammation in lymphoma.

In Malignant Lymphomas: Biology and Molecular Pathogenesis, (Lenz G., Pasqualuci L., eds.), pp. 315-333, Springer, 2014


Carlo-Stella C., Guidetti A., Santoro A. Inflammation and lymphoma: therapeutic implications.

In Hodgkin and Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy, (Carbone A., ed.), pp. 128-40, Future Medicine Ltd, 2015